Imidazoline antihypertensive drugs: a critical review on their mechanism of action

Pharmacology & Therapeutics
B Szabo

Abstract

It was long thought that the prototypical centrally acting antihypertensive drug clonidine lowers sympathetic tone by activating alpha(2)-adrenoceptors in the brain stem. Supported by the development of two new centrally acting drugs, rilmenidine and moxonidine, the imidazoline hypothesis evolved recently. It assumes the existence of a new group of receptors, the imidazoline receptors, and attributes the sympathoinhibition to activation of I(1) imidazoline receptors in the medulla oblongata. This review analyzes the mechanism of action of clonidine-like drugs, with special attention given to the imidazoline hypothesis. Two conclusions are drawn. The first is that the arguments against the imidazoline hypothesis outweigh the observations that support it and that the sympathoinhibitory effects of clonidine-like drugs are best explained by activation of alpha(2)-adrenoceptors. The second conclusion is that this class of drugs lowers sympathetic tone not only by a primary action in cardiovascular regulatory centres in the medulla oblongata. Peripheral presynaptic inhibition of transmitter release from postganglionic sympathetic neurons contributes to the overall sympathoinhibition.

References

Jan 15, 1979·European Journal of Pharmacology·G J GreenM S Yates
Mar 1, 1992·British Journal of Pharmacology·F SannajustJ Sassard
Mar 24, 1992·European Journal of Pharmacology·M F Suaud-ChagnyF Gonon
Jul 1, 1992·Journal of Cardiovascular Pharmacology·B SzaboK Starke
Mar 1, 1992·British Journal of Clinical Pharmacology·G J MacpheeJ L Reid
Mar 26, 1991·European Journal of Pharmacology·R E GomezD J Reis
Apr 1, 1991·Anesthesiology·J C Eisenach, C Y Tong
Jan 1, 1990·Life Sciences·S RegunathanD J Reis
Aug 1, 1991·Journal of Autonomic Pharmacology·C A HamiltonJ L Reid
Jan 1, 1987·Journal of Cardiovascular Pharmacology·L FerderF Medina
Apr 25, 1989·European Journal of Pharmacology·G BriccaP Bousquet
Mar 14, 1989·European Journal of Pharmacology·G BriccaP Bousquet
Sep 1, 1989·British Journal of Pharmacology·P MontastrucJ L Montastruc
Jan 1, 1988·Naunyn-Schmiedeberg's Archives of Pharmacology·T KuboY Misu
Sep 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·J N SinhaK P Bhargava
Feb 24, 1988·The American Journal of Cardiology·E Koenig-BerardC Labrid
Feb 24, 1988·The American Journal of Cardiology·J P FillastreJ Schwartz

❮ Previous
Next ❯

Citations

Jan 18, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Rodney A VelliquettePaul Ernsberger
Jun 20, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Paul Ernsberger, Richard J Koletsky
Mar 4, 2006·Psychopharmacology·Samir Kumar PraharajSachin Gandotra
Mar 19, 2013·European Journal of Pharmacology·Zoltán S ZádoriKlára Gyires
Jan 9, 2014·Physiological Reports·Elenia CinelliDonatella Mutolo
Nov 14, 2008·Stress : the International Journal on the Biology of Stress·Karen L SmithDavid P Finn
Mar 29, 2014·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·J A Lowry, J T Brown
Jan 7, 2016·European Journal of Medicinal Chemistry·Riham F George, Dalia O Saleh
May 9, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Paweł WiczlingRoman Kaliszan
Sep 9, 2008·Autonomic Neuroscience : Basic & Clinical·E B Monroy-OrdoñezD Centurión
Feb 11, 2004·British Journal of Pharmacology·Nathalie NiederhofferKlaus Starke
Sep 8, 2011·The Journal of Clinical Hypertension·Wanpen VongpatanasinRonald G Victor
Mar 21, 2006·Comptes rendus biologies·Caroline ProuillacGhassoub Rima
Jun 23, 2004·International Journal of Clinical Practice·P J LumbA S Wierzbicki
Dec 11, 2008·Basic & Clinical Pharmacology & Toxicology·Eduardo MouraMaria Augusta Vieira-Coelho
May 2, 2012·Journal of Neuroimmunology·Sam D PerezDenise L Bellinger
Sep 26, 2012·Expert Opinion on Therapeutic Patents·Xianghong Guan, Yongzhou Hu
Dec 10, 2003·Expert Opinion on Emerging Drugs·J A Whitworth
Aug 20, 2005·European Journal of Pharmacology·Naomi Cambridge, Emma S J Robinson
Aug 11, 2015·Journal of Advanced Research·Noha N Nassar, Abdel A Abdel-Rahman
Jun 23, 2007·Neurochemistry International·Salomon Z Langer
May 31, 2011·Biochemical and Biophysical Research Communications·Young-Hwan KimSeungsoo Chung
Sep 15, 2012·European Journal of Pharmacology·Mahmoud M El-MasAmal G Omar
Nov 17, 2007·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Alejandra Salerno, Isabel A Perillo
Nov 1, 2018·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Michael S ToceEdward W Boyer
Apr 7, 2007·Journal of Cardiovascular Pharmacology·Mahmoud M El-Mas, Abdel A Abdel-Rahman
Oct 27, 2011·Pharmazie in unserer Zeit·Klaus Starke
Nov 28, 2013·Journal of Hypertension·Kristy L JacksonGeoffrey A Head
Apr 6, 2006·The Journal of Pharmacology and Experimental Therapeutics·Noha Nassar, Abdel A Abdel-Rahman
May 20, 2005·The Journal of Pharmacology and Experimental Therapeutics·Jian Zhang, Abdel A Abdel-Rahman
Oct 15, 2003·The Journal of Pharmacology and Experimental Therapeutics·Rodney A Velliquette, Paul Ernsberger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.